Rationale and Design of a Multicentre, Randomized, Placebo-Controlled Trial of Mirabegron, a Beta3-Adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients with Structural Heart Disease Beta3-Left Ventricular Hypertrophy (Beta3-Lvh) (Vol 5, Pg 830, 2018)

AuthID
 P-00Q-188
1
Author(s)
Document Type
Correction
Year published
2018
Published
in ESC HEART FAILURE, ISSN: 2055-5822
Volume: 5, Issue: 6, Pages: 1199-1199 (1)
Indexing
Wos®
Google Scholar®
Publication Identifiers
Wos: WOS:000453876800028
Source Identifiers
ISSN: 2055-5822
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service